Cees G. M. Kallenberg

Cees G. M. Kallenberg's AcademicInfluence.com Rankings

Philosophy

#6862

World Rank

#9972

Historical Rank

Logic

#3956

World Rank

#5191

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Cees G. M. Kallenberg's Degrees

Doctorate Medicine University of Amsterdam
PhD Medicine University of Amsterdam

Why Is Cees G. M. Kallenberg Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Cees G. M. Kallenberg's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Rituximab versus cyclophosphamide for ANCA-associated vasculitis. (2010) (1810)
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis (2012) (885)
Association of Chronic Nasal Carriage of Staphylococcus aureus and Higher Relapse Rates in Wegener Granulomatosis (1994) (729)
Efficacy of remission-induction regimens for ANCA-associated vasculitis. (2013) (581)
International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies (2013) (471)
Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. (2010) (444)
Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome. (2007) (356)
Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. (2014) (339)
Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. (2002) (333)
Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. (2010) (319)
The complement system in systemic autoimmune disease. (2010) (314)
Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis (2017) (270)
Transancestral mapping and genetic load in systemic lupus erythematosus (2017) (253)
Antiproteinase 3- and antimyeloperoxidase-associated vasculitis. (2000) (222)
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. (2011) (222)
Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides (2006) (211)
Leukocyte activation in sepsis; correlations with disease state and mortality (2000) (207)
Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study (2011) (204)
Health-related quality of life, employment and disability in patients with Sjogren's syndrome. (2009) (200)
Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases (1993) (195)
Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis. (2002) (191)
Complement Activation Is Involved in Renal Damage in Human Antineutrophil Cytoplasmic Autoantibody Associated Pauci-Immune Vasculitis (2009) (189)
Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission. (2008) (187)
Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission. (2007) (184)
CYCLOPHOSPHAMIDE AND SUPPRESSOR CELL FUNCTION (1981) (180)
The Effect of Two Different Dosages of Intravenous Immunoglobulin on the Incidence of Recurrent Infections in Patients with Primary Hypogammaglobulinemia (2001) (178)
Accelerated atherosclerosis in patients with Wegener’s granulomatosis (2004) (165)
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. (2011) (163)
EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis (2010) (159)
T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis (WG) (1994) (152)
Progression of salivary gland dysfunction in patients with Sjögren’s syndrome (2006) (147)
High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus (2011) (145)
ANCA-associated vasculitides—advances in pathogenesis and treatment (2010) (143)
Pathogenesis of ANCA-associated vasculitides (2011) (141)
Staphylococcus aureus and Wegener's granulomatosis (2001) (136)
Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus (2006) (134)
The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. (2001) (130)
Disturbed Th1, Th2, Th17 and T(reg) balance in patients with systemic lupus erythematosus. (2011) (128)
Pathogenesis of PR3-ANCA associated vasculitis. (2008) (127)
Key advances in the clinical approach to ANCA-associated vasculitis (2014) (126)
Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study. (2003) (125)
European therapeutic trials in ANCA‐associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials EUROPEAN COMMUNITY STUDY GROUP ON CLINICAL TRIALS IN SYSTEMIC VASCULITIS ECSYSVASTRIAL (BMHl‐Cr93‐1078) (1995) (125)
Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 (2016) (122)
High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis. (2012) (119)
Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. (2015) (119)
Neutrophil‐activating potential of antineutrophil cytoplasm autoantibodies (2003) (116)
Preclinical validation of salivary biomarkers for primary Sjögren's syndrome (2010) (115)
Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus (2011) (112)
Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. (1996) (111)
Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis (2011) (109)
The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long term observation (1997) (108)
The Fc gamma RIIIA-158F allele is a risk factor for systemic lupus erythematosus (1998) (107)
The environment, geoepidemiology and ANCA-associated vasculitides. (2010) (107)
Neutrophil‐Related Gene Expression and Low‐Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2015) (106)
Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single center. (2012) (103)
Churg-Strauss syndrome: just one disease entity? (2005) (103)
Identification of autoantibody biomarkers for primary Sjögren's syndrome using protein microarrays (2011) (98)
Epstein-Barr Virus–DNA Load Monitoring Late After Lung Transplantation: A Surrogate Marker of the Degree of Immunosuppression and a Safe Guide to Reduce Immunosuppression (2007) (98)
Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. (2004) (98)
Monocyte activation in patients with Wegener’s granulomatosis (1999) (97)
Regulation of Cytokine‐Induced HIF‐1α Expression in Rheumatoid Synovial Fibroblasts (2007) (96)
The prototypic tissue pentraxin PTX3, in contrast to the short pentraxin serum amyloid P, inhibits phagocytosis of late apoptotic neutrophils by macrophages. (2004) (96)
The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis (2010) (96)
Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glomerulonephritis. (1998) (96)
Serum amyloid P component binds to late apoptotic cells and mediates their uptake by monocyte-derived macrophages. (2003) (93)
Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasone-loaded AbEsel liposomes. (2008) (90)
ANCA-negative pauci-immune crescentic glomerulonephritis (2009) (86)
Pathophysiology of ANCA-Associated Small Vessel Vasculitis (2010) (86)
Patients' perceptions of the effects of systemic lupus erythematosus on health, function, income, and interpersonal relationships: a comparison with Wegener's granulomatosis. (2002) (84)
Anti-C1q autoantibodies. (2008) (82)
Autoantibodies against Protective Molecules—C1q, C‐Reactive Protein, Serum Amyloid P, Mannose‐Binding Lectin, and Apolipoprotein A1 (2007) (82)
Reduced number and impaired function of circulating progenitor cells in patients with systemic lupus erythematosus (2007) (82)
Pathogenesis of ANCA-associated vasculitis: new possibilities for intervention. (2013) (80)
Vasculitis and infections: Contribution to the issue of autoimmunity reviews devoted to “autoimmunity and infection” (2008) (79)
Urinary CD4+ effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. (2009) (79)
Coexpression of CD177 and membrane proteinase 3 on neutrophils in antineutrophil cytoplasmic autoantibody-associated systemic vasculitis: anti-proteinase 3-mediated neutrophil activation is independent of the role of CD177-expressing neutrophils. (2009) (79)
Site-Specific Inhibition of Glomerulonephritis Progression by Targeted Delivery of Dexamethasone to Glomerular Endothelium (2007) (78)
Treatment of Mucosa-associated Lymphoid Tissue Lymphoma in Sjögren’s Syndrome: A Retrospective Clinical Study (2011) (78)
Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjögren's syndrome: data from a placebo-controlled clinical trial (2012) (78)
Bacterial DNA motifs trigger ANCA production in ANCA-associated vasculitis in remission. (2011) (78)
Systems biology analysis of Sjögren's syndrome and mucosa-associated lymphoid tissue lymphoma in parotid glands. (2009) (76)
Molecular genetic analyses of human NKG2C (KLRC2) gene deletion. (2004) (76)
Rats and mice immunised with chimeric human/mouse proteinase 3 produce autoantibodies to mouse Pr3 and rat granulocytes (2007) (76)
Myeloperoxidase–Antineutrophil Cytoplasmic Antibody (ANCA)–Positive and ANCA‐Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets (2016) (74)
Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors (2008) (74)
Hypoxia inducible factor-1-alpha (HIF-1alpha) is related to both angiogenesis and inflammation in rheumatoid arthritis. (2009) (71)
Infectious triggers for vasculitis (2014) (70)
Clinical associations of antiribonucleoprotein antibodies in patients with systemic lupus erythematosus. (1990) (69)
Antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis (2007) (69)
Ultraviolet light and cutaneous lupus (2006) (68)
Association of small life events with self reports of tic severity in pediatric and adult tic disorder patients: a prospective longitudinal study. (2004) (67)
Relative Contribution of Attention-Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, and Tic Severity to Social and Behavioral Problems in Tic Disorders (2004) (66)
Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease (2011) (66)
Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis. (2007) (65)
Increased expression of costimulatory markers CD134 and CD80 on interleukin-17 producing T cells in patients with systemic lupus erythematosus (2010) (65)
T-helper cells as new players in ANCA-associated vasculitides (2011) (65)
Increased Expression of Toll-Like Receptors by Monocytes and Natural Killer Cells in ANCA-Associated Vasculitis (2011) (64)
Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. (2009) (63)
New advances in the pathogenesis of ANCA-associated vasculitides. (2009) (62)
Cellular immunity in Wegener's granulomatosis: characterizing T lymphocytes. (2009) (62)
Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. (2011) (61)
Parotid sialography for diagnosing Sjögren syndrome. (2002) (61)
Abundance of the long pentraxin PTX3 at sites of leukocytoclastic lesions in patients with small-vessel vasculitis. (2006) (61)
B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjögren's syndrome: a double-blind, placebo-controlled study. (2011) (61)
Influenza vaccination in systemic lupus erythematosus: safe and protective? (2007) (60)
Longitudinal study on premature atherosclerosis in patients with systemic lupus erythematosus. (2009) (60)
Bacterial infections in Wegener's granulomatosis: mechanisms potentially involved in autoimmune pathogenesis (2011) (60)
Urinary T cells in active lupus nephritis show an effector memory phenotype (2010) (59)
Urine levels of HMGB1 in Systemic Lupus Erythematosus patients with and without renal manifestations (2012) (57)
Pulmonary function in systemic lupus erythematosus is related to distinct clinical, serologic, and nailfold capillary patterns. (1992) (57)
Pathogenesis of ANCA-Associated Vasculitis, an Update (2011) (57)
Is disturbed clearance of apoptotic keratinocytes responsible for UVB-induced inflammatory skin lesions in systemic lupus erythematosus? (2006) (56)
Altered B cell balance, but unaffected B cell capacity to limit monocyte activation in anti-neutrophil cytoplasmic antibody-associated vasculitis in remission. (2014) (56)
Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial. (2016) (55)
Lack of effect of intravenous immunoglobulins on tics: a double-blind placebo-controlled study. (2004) (55)
Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy (2012) (54)
Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosis (2011) (54)
Staphylococcal acid phosphatase binds to endothelial cells via charge interaction; a pathogenic role in Wegener’s granulomatosis? (2000) (54)
Podocyte expression of MHC class I and II and intercellular adhesion molecule‐1 (ICAM‐1) in experimental pauci‐immune crescentic glomerulonephritis (1994) (53)
Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study. (2009) (53)
Renal expression of matrix metalloproteinases in human ANCA-associated glomerulonephritis. (2004) (53)
Role of the Fcgamma receptor IIA polymorphism in the antiphospholipid syndrome: an international meta-analysis. (2003) (53)
Pathogenesis and treatment of ANCA-associated vasculitides. (2015) (52)
Hypoxia-inducible factor-1 as regulator of angiogenesis in rheumatoid arthritis - therapeutic implications. (2010) (52)
Immune regulatory mechanisms in ANCA-associated vasculitides. (2011) (52)
The future of damage assessment in vasculitis. (2007) (51)
Systems analysis of primary Sjögren's syndrome pathogenesis in salivary glands identifies shared pathways in human and a mouse model (2012) (51)
Overlapping syndromes, undifferentiated connective tissue disease, and other fibrosing conditions (1992) (50)
FoxP3+ CD4+ T cells in systemic autoimmune diseases: the delicate balance between true regulatory T cells and effector Th-17 cells. (2011) (49)
Review : Serological markers of disease activity in systemic lupus erythematosus (1995) (49)
Late breaking clinical trials 1 (2011) (48)
Expression and regulation of HIF-1alpha in macrophages under inflammatory conditions; significant reduction of VEGF by CaMKII inhibitor (2010) (48)
Daily physical activity in ankylosing spondylitis: validity and reliability of the IPAQ and SQUASH and the relation with clinical assessments (2013) (47)
The effect of three years of TNF alpha blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study (2012) (47)
Constitutive membrane expression of proteinase 3 (PR3) and neutrophil activation by anti‐PR3 antibodies (2004) (47)
The Fc gammaRIIIA-158F allele is a risk factor for systemic lupus erythematosus. (1998) (47)
Review article: The role of CD4+ T cells in ANCA‐associated systemic vasculitis (2009) (47)
Are cytokines and chemokines suitable biomarkers for Takayasu arteritis? (2017) (47)
New insights into the pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis. (2002) (46)
Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. (2005) (46)
Granuloma formation in ANCA‐associated vasculitides (2009) (46)
Opsonization of late apoptotic cells by systemic lupus erythematosus autoantibodies inhibits their uptake via an Fcgamma receptor-dependent mechanism. (2007) (46)
AGE and their receptor RAGE in systemic autoimmune diseases: An inflammation propagating factor contributing to accelerated atherosclerosis (2009) (46)
Serum MMP-3 Level as a Biomarker for Monitoring and Predicting Response to Etanercept Treatment in Ankylosing Spondylitis (2011) (46)
The diagnosis and classification of microscopic polyangiitis. (2014) (46)
Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2018) (45)
HLA-DR4, DR13(6) and the ancestral haplotype A1B8DR3 are associated with ANCA-associated vasculitis and Wegener's granulomatosis. (2009) (44)
Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis? (2018) (44)
Baseline predictors of response to TNF-&agr; blocking therapy in ankylosing spondylitis (2012) (44)
Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide. (1993) (43)
Association of common cold with exacerbations in pediatric but not adult patients with tic disorder: a prospective longitudinal study. (2005) (43)
Membrane-bound proteinase 3 and its receptors: relevance for the pathogenesis of Wegener's Granulomatosis. (2009) (42)
Increased frequency of circulating IL-21 producing Th-cells in patients with granulomatosis with polyangiitis (GPA) (2013) (42)
Image analysis: a novel approach for the quantification of antineutrophil cytoplasmic antibody levels in patients with Wegener's granulomatosis. (2003) (42)
CD4‐Positive Effector Memory T Cells Participate in Disease Expression in ANCA‐Associated Vasculitis (2007) (42)
Plasma levels of soluble IL-2R, soluble CD30, IL-10 and BAFF during follow-up in PR3-ANCA-associated vasculitis: associations with disease activity and relapse (2006) (41)
The Future of Biologic Agents in the Treatment of Sjögren’s Syndrome (2007) (40)
Antineutrophil Cytoplasmic Autoantibodies with Specificity for Myeloperoxidase (1996) (39)
Risk factors and early detection of atherosclerosis in rheumatoid arthritis (2010) (39)
Toll-like receptor 9 activation enhances B cell activating factor and interleukin-21 induced anti-proteinase 3 autoantibody production in vitro. (2016) (38)
The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. (2018) (38)
Renal expression of endothelial and inducible nitric oxide synthase, and formation of peroxynitrite‐modified proteins and reactive oxygen species in Wegener's granulomatosis (2001) (38)
Human anti-neutrophil cytoplasm autoantibodies to proteinase 3 (PR3-ANCA) bind to neutrophils. (2005) (38)
Urinary CD8+ T-cell counts discriminate between active and inactive lupus nephritis (2013) (38)
Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis (2001) (37)
Cutaneous reactions to captopril (1984) (36)
No effects of bosentan on microvasculature in patients with limited cutaneous systemic sclerosis (2009) (35)
Plasma Factors in Severe Early-Onset Preeclampsia Do Not Substantially Alter Endothelial Gene Expression In Vitro (2005) (35)
Oral and ocular manifestations in Sjögren's syndrome. (2002) (35)
Acute hepatitis B in a healthcare worker: a case report of genuine vaccination failure. (2009) (35)
What have we learned from clinical trials in primary Sjögren's syndrome about pathogenesis? (2011) (35)
Higher anti‐heparan sulphate reactivity during systemic lupus erythematosus (SLE) disease exacerbations with renal manifestations; a long term prospective analysis (1993) (34)
Urinary matrix metalloproteinases reflect renal damage in anti-neutrophil cytoplasm autoantibody-associated vasculitis. (2007) (34)
Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point? (2011) (34)
Differential Expression of Granulopoiesis Related Genes in Neutrophil Subsets Distinguished by Membrane Expression of CD177 (2011) (34)
Is serum HMGB1 a biomarker in ANCA-associated vasculitis? (2013) (34)
Ig Gene Analysis Reveals Altered Selective Pressures on Ig-Producing Cells in Parotid Glands of Primary Sjögren’s Syndrome Patients (2015) (33)
Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3–Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2017) (33)
Plasma kynurenine and related measures in tic disorder patients (2007) (33)
The BVAS is an independent predictor of cardiovascular events and cardiovascular disease-related mortality in patients with ANCA-associated vasculitis: A study of 504 cases in a single Chinese center. (2018) (32)
Therapy-resistent lupus skin disease successfully treated with rituximab. (2006) (32)
EASI—The European Autoimmunity Standardisation Initiative (2007) (32)
Comparison of lacrimal and salivary gland involvement in Sjögren's syndrome. (2003) (32)
Dysregulated neutrophil--endothelial interaction in antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides: implications for pathogenesis and disease intervention. (2011) (31)
Activation, Apoptosis, and Clearance of Neutrophils in Wegener's Granulomatosis (2005) (30)
Bronchoalveolar lavage cell analysis and lung function impairment in patients with systemic lupus erythematosus (SLE) (1993) (30)
Accelerated Atherosclerosis in Patients with Systemic Autoimmune Diseases (2005) (30)
Does reduction of disease activity improve early markers of cardiovascular disease in newly diagnosed rheumatoid arthritis patients? (2015) (30)
Anti-neutrophil cytoplasmic autoantibody pathogenicity revisited: pathogenic versus non-pathogenic anti-neutrophil cytoplasmic autoantibody. (2014) (30)
Current and future challenges in primary Sjögren's syndrome. (2012) (29)
Reactivity against Complementary Proteinase-3 Is Not Increased in Patients with PR3-ANCA-Associated Vasculitis (2011) (29)
Apoptosis in Human Skin: Role in Pathogenesis of Various Diseases and Relevance for Therapy (2005) (28)
Pauci-immune necrotizing glomerulonephritis. (2010) (28)
Enhanced endothelium-dependent microvascular responses in patients with Wegener's granulomatosis. (2007) (28)
Quantification of Epstein-Barr virus-DNA load in lung transplant recipients: a comparison of plasma versus whole blood. (2008) (27)
Peripheral CD5+ B Cells in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2015) (27)
Use of mycophenolic acid in non-transplant renal diseases. (2007) (27)
Emerging role of high mobility group box 1 in ANCA-associated vasculitis. (2015) (27)
Genetic loci of Staphylococcus aureus associated with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (2017) (26)
Cytokines and soluble adhesion molecules in children and adolescents with a tic disorder (2010) (26)
Native and recombinant proteins to analyze auto-antibodies to myeloperoxidase in pauci-immune crescentic glomerulonephritis. (2001) (26)
Advances in pathogenesis and treatment of ANCA-associated vasculitis. (2014) (25)
Fcγ receptors in the initiation and progression of systemic lupus erythematosus (2003) (25)
Patients with humoral primary immunodeficiency do not develop protective anti-influenza antibody titers after vaccination with trivalent subunit influenza vaccine. (2010) (25)
Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab (2014) (25)
The R-H polymorphism of FCgamma receptor IIa as a risk factor for systemic lupus erythematosus is independent of single-nucleotide polymorphisms in the interleukin-10 gene promoter. (2002) (25)
Absence of In Vivo Generalized Pro-Inflammatory Endothelial Activation in Severe, Early-Onset Preeclampsia (2005) (24)
Increased seroreactivity in tic disorder patients to a 60 kDa protein band from a neuronal cell line (2003) (24)
Membrane proteinase 3 expression on resting neutrophils as a pathogenic factor in PR3-ANCA-associated vasculitis. (2003) (24)
Complement is crucial in the pathogenesis of ANCA-associated vasculitis. (2013) (24)
Genetics of ANCA-associated vasculitides. (2002) (24)
Usefulness of antineutrophil cytoplasmic autoantibodies in diagnosing and managing systemic vasculitis. (2016) (23)
Pulmonary: renal syndrome with a focus on anti-GBM disease. (2011) (23)
Pulmonary diffusing capacity disturbances are related to nailfold capillary changes in patients with Raynauds's phenomenon with and without an underlying connective tissue disease (1990) (23)
Towards precision medicine in ANCA-associated vasculitis. (2018) (23)
How to assess treatment efficacy in Sjögren's syndrome? (2012) (23)
Recombinant proteinase 3 produced in different expression systems: recognition by anti-PR3 antibodies. (2000) (23)
Low anti-staphylococcal IgG responses in granulomatosis with polyangiitis patients despite long-term Staphylococcus aureus exposure (2015) (23)
Cell-mediated immune responses to inactivated trivalent influenza-vaccination are decreased in patients with common variable immunodeficiency. (2011) (22)
Patients with Wegener's granulomatosis: a long-term follow-up study. (2010) (22)
The Last Classification of Vasculitis (2008) (22)
The association of serum calprotectin (S100A8/S100A9) levels with disease relapses in PR3‐ANCA‐associated vasculitis (2016) (22)
M2 macrophage is the predominant phenotype in airways inflammatory lesions in patients with granulomatosis with polyangiitis (2017) (22)
The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2016) (21)
Successful treatment of ulcerating livedo reticularis with infusions of prostacyelin (1992) (21)
Circulating Angiopoietin-2 as a Biomarker in ANCA-Associated Vasculitis (2012) (21)
Anti‐neutrophil cytoplasmic antibody (ANCA)‐associated vasculitis: where to go? (2011) (21)
Design of the Rituximab in ANCA-Associated Vasculitis (RAVE) Trial (2011) (21)
Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2019) (21)
Cell-mediated immune responses to influenza vaccination in Wegener's granulomatosis (2009) (21)
Diversity of PR3-ANCA Epitope Specificity in Wegener's Granulomatosis. Analysis Using the Biosensor Technology (2003) (21)
High mobility group box 1 ( HMGB 1 ) and anti-HMGB 1 antibodies and their relation to disease characteristics in systemic lupus erythematosus (2011) (20)
Quantitation of antibodies to nucleoribonucleoprotein by ELISA: relation between antibody levels and disease activity in patients with connective tissue disease. (1985) (20)
Inflammatory clearance of apoptotic cells after UVB challenge (2007) (20)
Could we abandon cyclophosphamide in systemic vasculitis and lupus nephritis? (2012) (19)
Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis. (2016) (19)
B-cell populations and sub-populations in Sjögren's syndrome. (2012) (19)
Fluctuations in anti-nRNP levels in patients with mixed connective tissue disease are related to disease activity as part of a polyclonal B cell response. (1986) (19)
Absence of Cross-Reactivity to Myeloperoxidase of Anti-Thyroid Microsomal Antibodies in Patients with Autoimmune Thyroid Diseases (2001) (19)
Impact of Serum High Mobility Group Box 1 and Soluble Receptor for Advanced Glycation End-Products on Subclinical Atherosclerosis in Patients with Granulomatosis with Polyangiitis (2014) (19)
Anti-neutrophil cytoplasm autoantibodies (ANCA) in autoimmune liver diseases. (1999) (18)
Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis (2012) (17)
Complement system activation in ANCA vasculitis: A translational success story? (2015) (17)
Standardised assessment of membrane proteinase 3 expression. Analysis in ANCA-associated vasculitis and controls (2007) (17)
Role for CaMKII Inhibition in Rheumatoid Arthritis (2009) (17)
The net effect of ANCA on neutrophil extracellular trap formation. (2018) (17)
The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. (2019) (17)
Autoantibodies vex the vasculature (2008) (17)
Autoantibodies to myeloperoxidase: clinical and pathophysiological significance (1998) (17)
High mobility group box 1 serum levels are increased in Behçet's disease, but not associated with disease activity or disease manifestations. (2015) (17)
Interstitial lung disease and myositis in a patient with simultaneously occurring sarcoidosis and scleroderma. (1993) (16)
Extended Follow-up of Treatment with Rituximab Versus Cyclophosphamide for Remission-Induction of ANCA-Associated Vasculitis : Which Subsets Are At Greatest Risk for Flare? (2011) (16)
Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis (2018) (16)
Antinuclear and antinative DNA antibodies during captopril treatment. (2009) (16)
T FcRIIIA158F allele is a risk factor for systemic lupus erythematosus (1998) (16)
Lack of Association of C-C Chemokine Receptor 5 Δ32 Deletion Status with Rheumatoid Arthritis, Systemic Lupus Erythematosus, Lupus Nephritis, and Disease Severity (2010) (16)
Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2019) (16)
Rituximab treatment in primary Sjogren's syndrome : A double-blind placebo controlled trial (2008) (15)
What is new with anti-neutrophil cytoplasmic antibodies: diagnostic, pathogenetic and therapeutic implications. (1999) (15)
Elevated binding of D8/17-specific monoclonal antibody to B lymphocytes in Tic disorder patients. (2004) (15)
Small artery elasticity is decreased in patients with systemic lupus erythematosus without increased intima media thickness (2010) (14)
Selective elimination of pathogenic synovial fluid T-cells from rheumatoid arthritis and juvenile idiopathic arthritis by targeted activation of Fas-apoptotic signaling. (2011) (14)
Anti-myeloperoxidase antibodies in Churg-Strauss syndrome (1993) (13)
What is the evidence for prophylactic antibiotic treatment in patients with systemic vasculitides? (2011) (13)
HLA-DR 4 , DR 13 ( 6 ) and the ancestral haplotype A 1 B 8 DR 3 are associated with ANCA-associated vasculitis and Wegener ’ s granulomatosis (2009) (12)
The impact factor of rheumatology journals: an analysis of 2008 and the recent 10 years (2010) (12)
Autoantibodies during captopril treatment. (1985) (12)
Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis (2017) (12)
Pulmonary diffusing capacity disturbances are related to nailfold capillary changes in patients with Raynaud's phenomenon with and without an underlying connective tissue disease. (1990) (12)
Fcgamma receptors in the initiation and progression of systemic lupus erythematosus. (2003) (11)
Increased accumulation of advanced glycation endproducts in patients with Wegener's granulomatosis (2009) (11)
Autoantibody Standardization in the Netherlands (2009) (11)
Treatment approaches in primary Sjogren syndrome. (2010) (11)
Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2017) (11)
High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins (2015) (11)
Retinoid X receptor beta polymorphisms do not explain functional differences in vitamins D and A response in Antineutrophil cytoplasmic antibody associated vasculitis patients (2009) (10)
Disease Activity, Glucocorticoid Exposure, and Rituximab Determine Body Composition Changes during Induction Treatment of ANCA‐Associated Vasculitis (2016) (9)
Antineutrophil cytoplasmic antibodies (ANCA) and vasculitis (1990) (9)
Esophageal hypomotility in primary and secondary Raynaud's phenomenon: comparison of esophageal scintigraphy with manometry. (1995) (9)
Pro: Cyclophosphamide in lupus nephritis. (2016) (9)
Recombinant protein to analyze autoantibodies to proteinase 3 in systemic vasculitis. (2003) (9)
9 Laboratory findings in the vasculitides (1997) (9)
Prognostic Value of Renal Hemodynamic Characteristics in Patients with Proliferative Lupus Nephritis (2007) (8)
Decreased capillary permeability and capillary density in patients with systemic sclerosis using large-window sodium fluorescein videodensitometry of the ankle. (2008) (8)
Expression of Class II-MHC Antigens on Alveolar and Bronchiolar Epithelial Cells in Fibrosing Alveolitis (1986) (7)
Treatment of ANCA-Associated Vasculitis, Where to Go? (2012) (7)
Immunoglobulin Concentrations and Infection Risk Among Patients with ANCA-Associated Vasculitis Treated with Rituximab or Cyclophosphamide. (2011) (7)
Autoantibodies against glomerular endothelial cells in anti‐neutrophil cytoplasmic autoantibody‐associated systemic vasculitis (2009) (7)
L3. Are mononuclear cells predominant actors of endothelial damage in vasculitis? (2013) (7)
FSAP‐mediated nucleosome release from late apoptotic cells is inhibited by autoantibodies present in SLE (2016) (7)
13 – ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES WITH SPECIFICITY FOR MYELOPEROXIDASE (2007) (7)
Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis (2021) (7)
Skin Autofluorescence, as Marker of Accumulation of Advanced Glycation Endproducts and of Cumulative Metabolic Stress, Is Not Increased in Patients with Systemic Sclerosis (2011) (7)
Pulmonary function in patients presenting with Raynaud's phenomenon without an underlying connective tissue disease. A prospective, longitudinal study. (1989) (6)
Hypoxia inducible factor-1-alpha (HIF-1α) is related to both angiogenesis and inflammation in rheumatoid arthritis (2006) (6)
Dying neutrophils in ANCA-associated vasculitis: good or bad guys? (2002) (6)
Vasculitis syndromes: Peripheral neuropathy in AAV—when vasculitis hits a nerve (2012) (6)
Combined brain and heart magnetic resonance imaging in systemic vasculitides: fiction or real need? (2018) (5)
Antineutrophil cytoplasmic antibodies (ANCA): current perspectives (1996) (5)
Combined Brain/Heart Magnetic Resonance Imaging in Systemic Lupus Erythematosus (2020) (5)
Anti-Neutrophil Cytoplasmic Antibodies (ANCA): New Tools in the Diagnosis and Follow-Up of Necrotizing Glomerulonephritis and Vasculitis (1991) (5)
B-cell therapy in antineutrophil cytoplasmic antibody-associated vasculitis. (2015) (5)
Efficacy Of Glucocorticoids To Treat Limited Flares In ANCA-Associated Vasculitis (2013) (5)
Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2018) (5)
Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis? (2014) (5)
Renal vasculitis in 2012: Reclassification and the introduction of biologicals (2013) (5)
Antimyeloperoxidase-associated Proliferative Glomerulonephritis: An Animal Model By Elisabeth Brouwer,* Minke G. Huitema,* Pieter A. Klok,~ (1993) (5)
Prevention of relapsing disease in anti-neutrophil cytoplasmic antibody related necrotizing small-vessel vasculitis: the role for autoantibody guided and anti-bacterial treatment (2001) (5)
Disease Activity, ANCA-Type, and Lipid Levels in ANCA-Associated Vasculitis. (2019) (5)
Response to ‘T-helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus?’ (2014) (4)
Co-expression of CD177 and membrane proteinase 3 on neutrophils in ANCA-associated vasculitis: Anti-PR3 mediated neutrophil activation is independent of CD177 expression (2008) (4)
The role of bacterial infections for the initiation and exacerbation of systemic vasculitis. (2004) (4)
Novel territory for neutrophils in the pathogenesis of ANCA-associated vasculitides. (2009) (4)
Association of poly(ADP-ribose) polymerase 1 and a novel candidate locus, LOC127086, with systemic lupus erythematosus (2007) (4)
Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis (2020) (4)
Hypoxia inducible factor-1-alpha ( HIF-1 alpha ) is related to both angiogenesis and inflammation in rheumatoid arthritis (2018) (4)
Increased frequency of circulating follicular helper T cells (T-fh) in patients with WG (2011) (3)
Pulmonary arterial hypertension in systemic lupus erythematosus: should we bother? (2009) (3)
Serum Biomarkers of Disease Activity in Longitudinal Assessment of Patients with ANCA‐Associated Vasculitis (2021) (3)
Do apoptotic cells accumulate in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation? Comment on the article by Kuhn et al. (2006) (3)
Smoking and increased apoptosis in patients with systemic lupus erythematosus: comment on the article by Costenbader et al. (2004) (3)
Refractory disease in autoimmune diseases. (2011) (3)
Standard therapeutic regimens for vasculitis (2001) (3)
Pulmonary Manifestations of Systemic Vasculitides (1998) (3)
CpG triggers ANCA production by blood-derived B cells from ANCA-associated vasculitis patients in clinical remission (2009) (3)
Evolving concepts in pathogenesis and treatment of ANCA‐associated systemic vasculitides (2009) (3)
Preferential Binding of Anti-Neutrophil Cytoplasmic Antibodies to an Unexpected Epitope of a Chimeric Proteinase 3 Mutant (2019) (2)
Damage in ANCA-associated vasculitis: Preliminary evidence for the ANCA-associated vasculitis index of damage (AVID). (2006) (2)
The Relation Between Daily Physical Activity Measured with the Accelerometer and Clinical Assessments in Patients with Ankylosing Spondylitis (2011) (2)
Are Anti-Nrnp Levels Specific Guides for Assessing Disease Activity in Patients with (Mixed) Connective Tissue Disease? (1985) (2)
B-cell-targeted therapy in rheumatic diseases (2006) (2)
Retreatment With Rituximab In The Rituximab In ANCA-Associated Vasculitis (RAVE) Trial (2013) (2)
Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis (2022) (2)
Autoantibodies and Vascular Inflammation (2012) (2)
Leukocyte Cell Adhesion Molecules in Vasculitis (2001) (2)
University of Groningen Reactivity against Complementary Proteinase-3 Is Not Increased in Patients with PR3-ANCA- Associated Vasculitis Tadema, (2011) (2)
SP0001 What Is New in Vasculitis? (2016) (2)
Laboratory diagnosis of ANA, anti-dsDNA- and anti-ENA- antibodies; recommendations following the outcomes of a questionaire (2010) (2)
Clinical immunology--autoimmunity in the Netherlands. (2014) (2)
Rituximab treatment in Sjogren's syndrome: Clinical-histological evidence of the efficacy of B-cell depletion (2006) (2)
Antibodies Against C1q (2019) (2)
What is new in systemic vasculitis? (2000) (2)
AB0910 Validity and reliability of the IPAQ and squash to assess daily physical activity in patients with ankylosing spondylitis (2013) (2)
Activation of a Latent Epitope Causing Differential Binding of Anti-Neutrophil Cytoplasmic Antibodies to Proteinase 3 (2022) (1)
Health-related quality of life, employment and disability in patients with Sjo¨gren’s syndrome (2009) (1)
Predictive Value of Selected Markers of Inflammation and Platelet Activation for Complete Remission in ANCA-Associated Vasculitis (2012) (1)
Letter to the Editor (Matters Arising) (2006) (1)
Why rheumatologists should be involved in the treatment of lupus nephritis (2008) (1)
222. PREFERENTIAL BINDING TO AN UNEXPECTED EPITOPE OF A CHIMERIC RECOMBINANT PROTEINASE 3 VARIANT BY ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES (2019) (1)
Etiopathogenesis of systemic autoimmune diseases. (2013) (1)
Occurrence of antibodies to bactericidal permeability increasing protein (BPI) in sera with perinuclear antineutrophil cytoplasmic antibody (P-ANCA) activity (1997) (1)
Disease-modifying Therapy in Vasculitides (2012) (1)
Antibody and cell-mediated responses to influenza vaccination in patients with systemic lupus erythematosus and, healthy controls (2008) (1)
Primary Sjogren's syndrome: Retreatment with rituximab and long-term follow-up. (2006) (1)
Increased Frequency of Circulating Follicular Helper T-Cells (T-FH) in Patients with Granulomatosis with Polyangiitis. (2011) (1)
HMGB1 Is An Important Mediator in Cutaneous Inflammation in Systemic Lupus Erythematosus (SLE) (2011) (1)
Anti‐neutrophil cytoplasmic antibodies and the endothelium: many ways to vasculitis (1997) (1)
172. THE ASSOCIATION OF DIFFERENCES IN LIPID PARAMETERS WITH DISEASE ACTIVITY IN ANCA-ASSOCIATED VASCULITIS (AAV) (2019) (1)
Chapter 12 – Antineutrophil Cytoplasmic Autoantibodies with Specificity for Myeloperoxidase (2014) (1)
ANCA-associated vasculitis: pathogenesis revisited (2004) (1)
Autoantibodies as Biomarkers for ANCA-Associated Vasculitides (2011) (1)
Systems Biology Analysis of Sjögren’s Syndrome and MALT Lymphoma Development in Parotid Glands (2008) (1)
In reply to 'rituximab and B-cell return in ANCA-associated vasculitis'. (2014) (1)
Chapter VI Anti-CD 3-induced and anti-Fas-induced apoptosis in systemic lupus erythematosus ( SLE ) (2001) (1)
ANCA: their clinical relevance (1996) (1)
VALIDITY AND RELIABILITY OF THE IPAQ AND SQUASH TO ASSESS DAILY PHYSICAL ACTIVITY IN PATIENTS WITH ANKYLOSING SPONDYLITIS (2012) (1)
Circulating leukocytes in anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis have increased expression of activation markers, but no increased expression of adhesion molecules (1997) (1)
University of Groningen Differential expression of granulopoiesis related genes in neutrophil subsets distinguished by membrane expression of CD177 Hu, (2014) (1)
Opsonization of late apoptotic cells by systemic lupus erythematosus (SLE) autoantibodies inhibits their uptake via an Fc gamma R-dependent mechanism (2007) (1)
PREVALENCE OF VERTEBRAL FRACTURES IN ANKYLOSING SPONDYLITIS PATIENTS WITH ACTIVE DISEASE (2010) (0)
CHAPTER 2 CD 4-positive effector memory T-cells participate in disease expression in ANCA-associated vasculitis (2019) (0)
CHAPTER 6 REDUCED NUMBER AND IMPAIRED FUNCTION OF CIRCULATING PROGENITOR CELLS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (2019) (0)
Small artery elasticity is decreased in patients with systemic lupus erythematosus without atherosclerosis and is related to accumulation of advanced glycation end products (2008) (0)
ANCA pathogenicity revisited: pathogenic versus non-pathogenic ANCA (2016) (0)
Chapter 4 Image analysis ; a novel approach for the quantification of antineutrophil cytoplasmic antibody levels in patients with Wegener ’ s Granulomatosis (2018) (0)
Systemic auto immune diseases: from pathogenesis to treatment. (2003) (0)
Induction of HIF-1alpha expression in monocytic cells during differentiation under nowhypoxic conditions and effect on production of pro-angiogenic factors (2007) (0)
Identification of autoantibody biomarkers for primary Sjögren's syndrome using protein microarrays (2011) (0)
[Vasculitis: a spectrum of divergent disease aspects with a common immunopathogenesis?]. (1987) (0)
Re-Occurring Proteinuria in a SLE Patient: Always Lupus Nephritis? (2017) (0)
University of Groningen Sjogren ' s syndrome (2010) (0)
Pathogenic mechanisms of autoantibodies (2007) (0)
Reduced number and impaired function of endothelial progenitor cells in patients with systemic lupus erythematosus (2007) (0)
Increased expression of costimulatory markers CD134 and CD80 on IL-17 producing T-cells in patients with systemic lupus erythematosus (2017) (0)
CHAPTER 7 ACCELERATED ATHEROSCLEROSIS IN PATIENTS WITH WEGENER ’ S GRANULOMATOSIS (2019) (0)
Skin autofluorescence, as measure of cumulative metabolic and oxidative stress, in relation to lipids in patients with systemic sclerosis (2008) (0)
University of Groningen Hypoxia inducible factor-1-alpha ( HIF-1 alpha ) is related to both angiogenesis and inflammation in rheumatoid arthritis (2017) (0)
Chapter 5 Native and recombinant proteins to analyze autoantibodies to myeloperoxidase in pauci-immune crescentic glomerulonephritis (2017) (0)
Genetic loci of Staphylococcus aureus associated with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (2017) (0)
List of Contributors (2019) (0)
Pathogenetic and clinical aspects of ANCA-associated vasculitis (2017) (0)
Vasculitis: current issues IP93. Pathogenesis of Vasculitis (2011) (0)
New etiopathogenic knowledge, or politics? Comment on the article by Falk et al Reply (2011) (0)
CHANGES IN BONE TURNOVER MARKERS IN PATIENTS WITH ANKYLOSING SPONDYLITIS DURING THE FIRST 6 MONTHS OF TNF-ALPHA BLOCKING THERAPY (2010) (0)
B cell phenotype and function in granulomatosis with polyangiitis Land (2016) (0)
Full Review B-cell therapy in antineutrophil cytoplasmic antibody-associated vasculitis (2015) (0)
Separate association with susceptibility or protection to systemic lupus erythematosus of interferon regulatory factor 5 (IRF5) polymorphisms (2007) (0)
The Specificity of the Autoimmune Response in Vasculitis (1991) (0)
University of Groningen Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors Hettema, (2015) (0)
Lupus. Preface. (2008) (0)
University of Groningen Low anti-staphylococcal IgG responses in granulomatosis with polyangiitis patients despite long-term Staphylococcus aureus exposure Glasner, (2015) (0)
CHAPTER 1 ACCELERATED ATHEROSCLEROSIS IN PATIENTS WITH SYSTEMIC AUTOIMMUNE DISEASES (2008) (0)
Quantitation ofantibodies tonucleoribonucleoprotein byELISA: relation between antibody levels anddisease activity inpatients withconnective tissue disease (1985) (0)
antibodies antigens referred to as anti-nuclear assessment of autoantibodies to cellular International recommendations for the (2013) (0)
[The significance of determining humoral defense factors: Ig isotypes, specific antibodies and complement]. (1988) (0)
Diagnostic and pathogenetic significance of autoantibodies in autoimmune liver diseases (2001) (0)
CHAPTER 8 PROGRESSION OF ATHEROSCLEROSIS IN PATIENTS WITH WEGENER ’ S GRANULOMATOSIS : A LONG-TERM FOLLOW-UP STUDY (2019) (0)
OP0058 Using Mass Spectrometry To Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in Anca-Associated Vasculitis (2016) (0)
The Hochberg: Rheumatology, 7e : Biology and immunopathogenesis of vasculitis Elisabeth Brouwer • Peter Heeringa • Cees G.M. Kallenberg (2018) (0)
CHAPTER 6 Functional defect of circulating regulatory CD 4 + T-cells in patients with Wegener ’ s granulomatosis in remission (2018) (0)
Influenza vaccination in ANCA-associated vasculitis Reply (2009) (0)
Chapter 7 ANCA-Associated Systemic Vasculitides: Mechanisms (2007) (0)
Serum levels of soluble receptor for advanced glycation end products in AA amyloidosis are increased and related to loss of renal function (2010) (0)
Plenary and parallel sessions (2001) (0)
Prevention of relapses in antineutrophil cytoplasmic antibody associated vasculitis by treatment based on autoantibody levels as detected by solid phase assay: a preliminary report (2001) (0)
[Agranulocytosis caused by niflumic acid (Infaryl)]. (1979) (0)
Induction of HIF-1 alpha expression during monocyte-macrophage differentiation and effect on production of pro-angiogenic factors (2007) (0)
C5a primes neutrophils for ANCA-mediated activation: role of P38 mitogen-activated protein kinase (2009) (0)
Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism (2023) (0)
THU0265 Early change in bone resorption predicts discontinuation of tumor necrosis factor-alpha blocking therapy in patients with ankylosing spondylitis (2013) (0)
Chapter 11 Neurobiology of Tourette ’ s syndrome : do immune factors really matter ? (2018) (0)
SP0149 Endothelial Damage in Anca-Associated Vasculitis (AAV) (2015) (0)
Identifying relevant determinants of in-hospital time to diagnosis for ANCA-associated vasculitis patients (2022) (0)
High mobility group box 1 levels are not associated with subclinical carotid atherosclerosis in patients with granulomatosis with polyangiitis but are reduced by glucocorticoids and statins (2012) (0)
Increased Circulating FoxP3(+) T-Cells in Patients with Granulomatosis with Polyangiitis Are Attributed to an Increase in the Non-Suppressor FoxP3(Low) CD45RO(+) T-Reg Cell Subpopulation. (2012) (0)
Apoptosis and autoantibodies in systemic lupus erythematosus (2001) (0)
Fluctuations inanti-nRNP levels inpatients with mixedconnective tissue disease arerelated todisease activity aspartofapolyclonal Bcell response (1986) (0)
FRI0295 Syndesmophytes are associated with higher bone turnover in ankylosing spondylitis patients with active disease (2013) (0)
CHAPTER 9 ENHANCED ENDOTHELIUM-DEPENDENT MICROVASCULAR RESPONSES IN PATIENTS WITH WEGENER ’ S GRANULOMATOSIS (2019) (0)
ATHEROSCLEROSIS IN PATIENTS WITH SYSTEMIC AUTOIMMUNE DISEASES (2008) (0)
Improvement in Ankylosing Spondylitis Disease Activity Score in Patients with Ankylosing Spondylitis Treated with Tumor Necrosis Factor-Alpha Blocking Therapy (2011) (0)
Unraveling the identity of FoxP3+ regulatory T-cells in GPA-patients (2013) (0)
Quality of life, employment and disability in patients with Sjogren's syndrome (2008) (0)
Commentary Staphylococcus aureus and Wegener ’ s granulomatosis (2015) (0)
Transplantation, immunology, inflammation (2002) (0)
Lupus Erythematosus ( SLE ) : relation to lymphocyte activation and disease activity (2001) (0)
CHAPTER 3 Disturbed Th 1 , Th 2 , Th 17 and Treg balance in patients with systemic lupus erythematosus (2017) (0)
154 – Biology and immunopathogenesis of vasculitis (2015) (0)
P2_19 High Bartonella Seroprevalence in Proteinase 3-Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (2017) (0)
053. CLINICAL UTILITY OF SERIAL MEASUREMENTS OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES TARGETING PROTEINASE 3 IN ANCA-ASSOCIATED VASCULITIS (2019) (0)
TUMOR NECROSIS FACTOR-ALPHA BLOCKING THERAPY IMPROVES QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS IN DAILY CLINICAL PRACTICE (2010) (0)
Opponent's comments. (2016) (0)
[The role of perinuclear antineutrophil granulocytes cytoplasmic antibodies in the diagnosis of vasculitis and chronic inflammatory diseases]. (1996) (0)
Relationship between age and bone turnover markers in patients with active ankylosing spondylitis (2009) (0)
Endothelial Progenitor Cells and cardiovascular risk in patients with Early Rheumatoid Arthritis (2014) (0)
Acute hepatitis B in a healthcare worker: A lesson in awareness of failure of hepatitis B vaccination (2009) (0)
SAT0370 Antineutrophil Cytoplasmic Antibody (ANCA) Type and Body Mass Index in Anca-Associated Vasculitis (2016) (0)
Value of positron emission tomography in diagnosis and follow-up of patients with Takayasu arteritis (2003) (0)
Co-trimoxazole in Wegener's granulomatosis - Reply (1996) (0)
C URRENT OPINION Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis? (2014) (0)
Auto-antigen expression of proteinase 3 on the membrane of neutrophils is dependent on phosphatidylinositol 3-kinase and P38 MAPkinase activity (2006) (0)
SAT0369 Weight Gain in Anca-Associated Vasculitis Is Independent of Glucocorticoid Dosing (2016) (0)
CYP450 polymorphism as a predictor of adverse effects and therapy response in patients with ANCA-AAV (2011) (0)
University of Groningen Is serum HMGB 1 a biomarker in ANCA-associated vasculitis ? (2013) (0)
APRIL and BAFF Levels After Rituximab Treatment in Patients with Primary Sjogren's Syndrome: A Placebo-Controlled Clinical Trial (2011) (0)
Progression and treatment evaluation in diseases affecting salivary glands (2010) (0)
[A patient with recurrent polychondritis, vasculitis and local focal glomerulonephritis]. (1988) (0)
Glands of Primary Sjögren's Syndrome Pressures on Ig-Producing Cells in Parotid Ig Gene Analysis Reveals Altered Selective (2015) (0)
Interleukin 10–1082 promoter polymorphism in inflammatory bowel disease is not associated with disease susceptibility or severity (1999) (0)
Chapter 7 Plasma kynurenine and tryptophan in Tourette ’ s and chronic motor tic disorder (2018) (0)
Leucocyte TLR expression in ANCA-AAV : differential expression by monocytes and NK cells (2011) (0)
Experimental Therapies in Sjögren’s Syndrome (2011) (0)
Systemic vasculitides, an introduction (2001) (0)
Early Reconstitution of Autoreactive B-Cells After Rituximab Treatment in Primary Sjogren's Syndrome (2011) (0)
B-Cell Depletion By Rituximab Affects the Distribution of Effector Th-Cell Subsets in Patients with ANCA Associated Vasculitis (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Cees G. M. Kallenberg?

Cees G. M. Kallenberg is affiliated with the following schools:

University of Groningen